<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of infections in patients with chronic lymphocytic leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of infections in patients with chronic lymphocytic leukemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of infections in patients with chronic lymphocytic leukemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vicki A Morrison, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bow, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H339658932"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Infections have a major impact on the clinical course of patients with chronic lymphocytic leukemia (CLL). Patients with CLL have underlying abnormalities in immune function related to the primary disease process in addition to defects in immune function related to the specific antileukemic therapies administered. The spectrum of infections in CLL patients has expanded with the use of therapies such as the alkylating agents (<a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>), purine analogs (eg, <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>), monoclonal antibodies (eg, <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>), Bruton tyrosine kinase inhibitors (eg, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>), phosphatidylinositol 3-kinase inhibitors (eg, <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>), and the B cell leukemia/lymphoma 2 inhibitor, <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>.</p><p>The approach to infection prevention will be reviewed here. The immune defects related to CLL and its therapy as well as the spectrum of infectious complications are discussed separately. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia"</a>.)</p><p>The management and complications of CLL are discussed separately. (See  <a class="medical medical_review" href="/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a> and  <a class="medical medical_review" href="/d/html/83749.html" rel="external">"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia"</a> and  <a class="medical medical_review" href="/d/html/4504.html" rel="external">"Overview of the complications of chronic lymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H339658996"><span class="h1">ANTIMICROBIAL PROPHYLAXIS</span></p><p class="headingAnchor" id="H2323636"><span class="h2">General approach</span><span class="headingEndMark"> — </span>As the immune defects caused by specific CLL therapies have significant impact on subsequent infectious complications, our prophylaxis recommendations vary depending upon the type of therapy used  (<a class="graphic graphic_table graphicRef95493" href="/d/graphic/95493.html" rel="external">table 1</a>). Additional considerations that impact antimicrobial prophylaxis in individual patients are treatment status (treatment naïve versus heavily pretreated) and past history of infections. There are no unique prophylaxis recommendations for older versus younger patients [<a href="#rid1">1</a>].</p><p>There have been no randomized trials evaluating the use of prophylactic antimicrobials in patients with CLL, and there are no evidence-based guidelines for antimicrobial prophylaxis in this population. Most recommendations for antimicrobial prophylaxis have been extrapolated from prophylactic regimens used in treatment trials as well as from anecdotal reports. </p><p>The National Comprehensive Cancer Network (NCCN) and the International Workshop on Chronic Lymphocytic Leukemia have developed supportive care guidelines for CLL patients based upon expert consensus opinion [<a href="#rid2">2-5</a>]. Our recommended approach takes these recommendations into consideration but also provides more specific recommendations based upon prophylaxis recommendations used in CLL treatment trials and infectious complications observed in these trials.</p><p class="headingAnchor" id="H2321845"><span class="h2">Indications based on CLL therapy</span><span class="headingEndMark"> — </span>The use of prophylactic antimicrobials in patients with CLL depends upon the treatment regimen and its associated immune defects  (<a class="graphic graphic_table graphicRef95493" href="/d/graphic/95493.html" rel="external">table 1</a>). Suggested prophylactic regimens (for those with an indication) are summarized in the following table  (<a class="graphic graphic_table graphicRef95619" href="/d/graphic/95619.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial prophylaxis is not advocated for patients with CLL who are not receiving active therapy or who are receiving an alkylating agent (eg, <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>), <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, or <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>. Instead, such patients are candidates for vigilant observation and early initiation of treatment if symptoms develop.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving a purine analog-based treatment regimen are at increased risk for several opportunistic infections. We use antiviral prophylaxis (against herpes simplex virus [HSV] and varicella-zoster virus [VZV]) in all patients receiving a purine analog. In those receiving a purine analog in combination with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> with or without an anti-CD20 monoclonal antibody, we also use <em>Pneumocystis</em> prophylaxis. (See <a class="local">'Purine analog therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients treated with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> are at increased risk for multiple opportunistic infections, including cytomegalovirus (CMV) reactivation. We use antiviral prophylaxis (against HSV and VZV) and <em>Pneumocystis</em> prophylaxis routinely in such patients, and we monitor patients weekly for CMV reactivation. (See <a class="local">'Alemtuzumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Pneumocystis</em> pneumonia has occurred in some patients receiving <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, or <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>. <em>Pneumocystis</em> prophylaxis is recommended with idelalisib and duvelisib therapy, and pre-emptive monitoring for CMV reactivation or infection is recommended when feasible. At present, there are no standard recommendations for antimicrobial prophylaxis with ibrutinib use. (See <a class="local">'Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors'</a> below.)</p><p></p><p class="headingAnchor" id="H339659004"><span class="h3">Alkylating agents</span><span class="headingEndMark"> — </span>The most frequent infections occurring in patients receiving <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, as a single agent or with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, are common bacterial infections. We do not use antimicrobial prophylaxis when these agents are used to treat CLL. Antimicrobial prophylaxis is also not recommended for patients receiving <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> as a single agent or in combination with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, chlorambucil, or <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> [<a href="#rid6">6-8</a>].</p><p class="headingAnchor" id="H339659020"><span class="h3">Purine analog therapy</span></p><p class="headingAnchor" id="H339659028"><span class="h4">Single-agent therapy</span><span class="headingEndMark"> — </span>Antiviral and <em>Pneumocystis</em> prophylaxis is advocated by some experts for patients receiving single-agent purine analog therapy [<a href="#rid5">5,9</a>]. In the guidelines for patients with non-Hodgkin lymphomas, the NCCN has recommended <em>Pneumocystis </em>prophylaxis for patients receiving a purine analog [<a href="#rid5">5</a>]. In contrast, in the guidelines for prevention and treatment of cancer-related infections, the NCCN has suggested that <em>Pneumocystis</em> prophylaxis be considered only in those receiving a purine analog in combination with another T cell-depleting agent until the CD4 count is &gt;200 cells/microL [<a href="#rid10">10</a>]. <em>Pneumocystis </em>prophylaxis has been advocated by some for use in older adult patients receiving a purine analog [<a href="#rid11">11</a>]. However, based upon data from large prospective oncology cooperative group CLL treatment trials in which <em>Pneumocystis</em> pneumonia occurred rarely, we do not suggest routine <em>Pneumocystis</em> prophylaxis for patients receiving single-agent purine analog therapy [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Indications'</a>.)</p><p>Prophylaxis against HSV and VZV has also been recommended by the NCCN for neutropenic patients receiving single-agent purine analog therapy [<a href="#rid10">10</a>]. We also suggest antiviral prophylaxis in such patients based upon findings from a large prospective oncology cooperative group CLL treatment trial [<a href="#rid12">12</a>].</p><p>Although the NCCN suggests that fluoroquinolone prophylaxis be considered in patients receiving purine analog therapy, findings from oncology cooperative group CLL trials do not support the need for this [<a href="#rid10">10,12</a>]; thus, we do not routinely use fluoroquinolone prophylaxis for patients receiving single-agent purine analog therapy. (See  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults", section on 'Guidelines'</a> and  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults", section on 'Intermediate-risk patients'</a>.)</p><p class="headingAnchor" id="H339659036"><span class="h4">Purine analog-anti-CD20 monoclonal antibody combination therapy</span><span class="headingEndMark"> — </span>Based upon findings from oncology cooperative group clinical trials, the addition of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> does not increase the risk of infectious complications [<a href="#rid13">13,14</a>]. In patients receiving this regimen, we use antiviral (HSV, VZV) prophylaxis during therapy and for 6 to 12 months after completion of therapy. We generally do not use <em>Pneumocystis</em> prophylaxis, although it may be considered on a case-by-case basis [<a href="#rid13">13-15</a>]. In contrast, the NCCN recommends both antiviral and <em>Pneumocystis</em> prophylaxis with any purine analog-based regimen [<a href="#rid5">5</a>].</p><p>For patients receiving pentostatin-rituximab, we give <em>Pneumocystis</em> and antiviral prophylaxis (against HSV and VZV) during therapy and for 6 to 12 months after completion of therapy [<a href="#rid16">16</a>]. We also give myeloid growth factor support with each cycle. </p><p class="headingAnchor" id="H339659044"><span class="h4">Purine analog-cyclophosphamide combination therapy</span><span class="headingEndMark"> — </span>For patients receiving fludarabine-cyclophosphamide, we use antiviral (against HSV, VZV) and <em>Pneumocystis</em> prophylaxis during therapy and for 6 to 12 months after completion of therapy [<a href="#rid17">17</a>]. We also give myeloid growth factor support with each cycle.</p><p class="headingAnchor" id="H339659052"><span class="h4">Purine analog-cyclophosphamide-anti-CD20 monoclonal antibody combination therapy</span><span class="headingEndMark"> — </span>In patients receiving three-drug combinations such as fludarabine-cyclophosphamide-rituximab and pentostatin-cyclophosphamide-rituximab, we use <em>Pneumocystis </em>and antiviral prophylaxis [<a href="#rid18">18-20</a>]. We give prophylaxis during therapy and for 6 to 12 months after completion of therapy [<a href="#rid20">20</a>]. We also give myeloid growth factor support with each cycle. With ofatumumab-fludarabine-cyclophosphamide therapy, we use myeloid growth factor support as well as <em>Pneumocystis</em> and antiviral prophylaxis [<a href="#rid21">21</a>]. For the fludarabine-cyclophosphamide-rituximab-lite regimen (low-dose <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, high-dose <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>), which may be used in older adult or frail patients, we use myeloid growth factor support as well as <em>Pneumocystis</em> and antiviral prophylaxis during therapy and for six months after therapy discontinuation [<a href="#rid22">22</a>]. </p><p class="headingAnchor" id="H264145543"><span class="h3">Anti-CD20 monoclonal antibodies</span><span class="headingEndMark"> — </span>When an anti-CD20 monoclonal antibody (eg, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>) is used as single-agent therapy, we do not use antimicrobial prophylaxis [<a href="#rid23">23</a>]. Likewise, when one of these agents is used in combination regimens with agents such as <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> or <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, we do not use antimicrobial prophylaxis [<a href="#rid24">24</a>]. However, in patients receiving a combination of an anti-CD20 monoclonal antibody and high-dose <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a>, we give <em>Pneumocystis</em> and herpesvirus (HSV, VZV) prophylaxis during therapy and for two months following treatment discontinuation [<a href="#rid25">25</a>]. Invasive fungal infections with obinutuzumab therapy have been reported anecdotally [<a href="#rid26">26</a>].</p><p>Another issue that arises with the use of these agents is the potential for hepatitis B or C reactivation. We suggest testing hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), and hepatitis C antibody (HCAb) prior to initiation of anti-CD20 monoclonal antibody therapy. If either HBsAg or HBcAb is positive, a quantitative hepatitis B viral load should be checked using the polymerase chain reaction (PCR). Patients who are receiving intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>) may be HBcAb positive due to passive transfer. In HBsAg-positive patients who are planning to receive anti-CD20 monoclonal antibody therapy, we give prophylactic antiviral therapy with activity against hepatitis B (eg, <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>, tenofovir) [<a href="#rid5">5,27</a>]. For those who are HBcAb positive, we also use prophylactic antiviral therapy. While receiving therapy with these agents, hepatitis B viral load should be monitored monthly. Anti-hepatitis B prophylaxis should be continued for up to one year after discontinuation of anti-CD20 monoclonal antibody therapy [<a href="#rid5">5</a>]. For active hepatitis B infection, consultation with a hepatitis expert is recommended. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p>The anti-CD20 monoclonal antibodies have been associated with progressive multifocal leukoencephalopathy (PML), but no prophylaxis exists. Clinicians should consider diagnostic evaluation in patients who present with suggestive signs and/or symptoms of PML. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Anti-CD20 monoclonal antibodies'</a> and  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H339659060"><span class="h3">Alemtuzumab</span><span class="headingEndMark"> — </span>We use antibacterial prophylaxis with a fluoroquinolone during therapy with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> [<a href="#rid10">10,15,28-30</a>]. In addition, we use <em>Pneumocystis</em> prophylaxis during alemtuzumab therapy as well as for two to six months after treatment discontinuation and for as long as the CD4 count is &lt;200 cells/microL [<a href="#rid10">10</a>]. We also give herpes prophylaxis (against HSV, VZV) during alemtuzumab therapy and for a minimum of two months after treatment discontinuation and for as long as the CD4 count is &lt;200 cells/microL [<a href="#rid10">10,15,28-30</a>]. Antifungal prophylaxis is not necessary with alemtuzumab alone but may be indicated for patients receiving combination therapy [<a href="#rid10">10,31</a>]. We also give myeloid growth factor support [<a href="#rid10">10,32</a>]. </p><p>CMV reactivation, which occurs in 4 to 29 percent of CLL patients receiving <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, is a significant infectious risk with alemtuzumab [<a href="#rid33">33</a>]. Despite the substantial risk of CMV reactivation, CMV prophylaxis is not typically used given the bone marrow toxicity associated with <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>. However, some experts give valganciclovir to prevent reactivation of CMV, or <a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">letermovir</a>, a newer antiviral agent with less bone marrow toxicity [<a href="#rid34">34,35</a>]. Instead of giving CMV prophylaxis, we suggest a pre-emptive approach involving weekly quantitative CMV PCR monitoring during alemtuzumab administration and for two months following completion of therapy [<a href="#rid10">10,31,36</a>]. The frequency of CMV testing may be decreased after the second month of therapy [<a href="#rid31">31</a>]. CMV PCR should also be checked in the setting of fever of unknown origin.</p><p>The issue of whether to institute therapy for CMV if viremia is present or only if the CMV viral load is increasing is controversial [<a href="#rid37">37</a>]. This is largely due to the fact that no cutoff viral load associated with CMV disease has been established. (See  <a class="medical medical_review" href="/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection", section on 'Predictive role'</a>.)</p><p class="headingAnchor" id="H15553093"><span class="h3">Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors</span><span class="headingEndMark"> — </span>There is limited but increasing evidence suggesting that the Bruton tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> is associated with invasive fungal infections, including <em>Pneumocystis</em> pneumonia and invasive aspergillosis, and that the phosphatidylinositol 3-kinase (PI3K) inhibitors, <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a> and <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>, are associated with <em>Pneumocystis</em> and CMV infections. Clinicians should have a high index of suspicion for these infections in patients receiving these agents, and the diagnosis should be sought in those with compatible signs and symptoms. At present, there are no standard recommendations for antimicrobial prophylaxis with ibrutinib or <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> use. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Bruton tyrosine kinase inhibitors'</a> and  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Phosphatidylinositol 3-kinase inhibitors'</a>.)</p><p><em>Pneumocystis </em>prophylaxis is recommended by the manufacturer, as well as us, in all patients receiving <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a> or <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a> [<a href="#rid38">38-40</a>]. Idelalisib or duvelisib should be suspended if <em>Pneumocystis </em>pneumonia is suspected and permanently discontinued if the diagnosis is confirmed.</p><p>In patients with a history of CMV infection or positive CMV serology receiving <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, the manufacturer recommends that regular clinical and laboratory monitoring for CMV infection be performed [<a href="#rid38">38</a>]. For patients who develop CMV infection while receiving idelalisib and in whom idelalisib is reinstituted, monitoring with CMV PCR or CMV antigenemia should be done at least monthly.</p><p>The manufacturer of <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a> suggests that clinicians consider the use of prophylactic antivirals to prevent CMV infection and reactivation [<a href="#rid40">40</a>]. For patients who develop CMV infection, duvelisib should be withheld until infection resolves. If duvelisib is resumed after CMV infection, monitoring with CMV PCR or CMV antigenemia should be done at least monthly.</p><p>For patients receiving either <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a> or <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>, we determine the appropriateness of CMV prophylaxis on a case-by-case basis, balancing the risk of CMV reactivation with the risk of toxicity from CMV prophylaxis. When prophylaxis is not given, we monitor patients with a history of CMV infection or positive CMV serology closely as outlined above.</p><p>Cases of PML have been reported in patients receiving <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> or <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, but no prophylaxis exists. Clinicians should consider diagnostic evaluation in patients who present with suggestive signs and/or symptoms of PML. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Bruton tyrosine kinase inhibitors'</a> and  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Phosphatidylinositol 3-kinase inhibitors'</a> and  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3467844288"><span class="h3">Lenalidomide</span><span class="headingEndMark"> — </span>At present, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, an immunomodulatory agent, has no treatment indication for patients with CLL outside of clinical trials. When lenalidomide is used as a single agent or in combination with an anti-CD20 monoclonal antibody or corticosteroids (as <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>), we recommend antiviral prophylaxis [<a href="#rid41">41,42</a>]. However, anti-<em>Pneumocystis</em> and antiviral prophylaxis is suggested for patients receiving lenalidomide in combination with <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid43">43,44</a>].</p><p class="headingAnchor" id="H921526652"><span class="h3">Venetoclax</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is a B cell leukemia/lymphoma 2 (BCL-2) inhibitor that has not been definitively associated with an increased risk of opportunistic infections. Antimicrobial prophylaxis is therefore not typically given with this agent. However, antiviral, antifungal, and/or <em>Pneumocystis</em> prophylaxis may be considered on a case-by-case basis in settings of prior opportunistic infections that could recrudesce and/or residual immune defects from prior CLL therapy. Because venetoclax is a cytochrome P450 substrate, there a multiple potential drug interactions; <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> is specifically contraindicated during the ramp-up phase of venetoclax initiation. Other azoles may also interact and consultation with specialists familiar with the use of these drugs when considering use (see  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Venetoclax'</a>). Specific interactions with other medications may be determined using the <a class="external" href="/drug-interactions">drug interaction program</a> included within UpToDate.</p><p class="headingAnchor" id="H2321852"><span class="h2">Hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>Patients with CLL who undergo hematopoietic cell transplantation (HCT) should receive antimicrobial prophylaxis regimens recommended for HCT recipients. Recommendations for such patients are provided separately. (See  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/16533.html" rel="external">"Prevention of viral infections in hematopoietic cell transplant recipients"</a>.)</p><p class="headingAnchor" id="H1207784361"><span class="h1">MYELOID GROWTH FACTORS</span><span class="headingEndMark"> — </span>The use of myeloid growth factors, such as granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF), in patients with CLL who are expected to have neutropenia should follow established guidelines for the management of infections in such patients. The Infectious Diseases Society of America guidelines suggest that the prophylactic use of myeloid growth factors be considered for afebrile patients receiving a treatment regimen for which the anticipated risk of fever and neutropenia is ≥20 percent [<a href="#rid45">45</a>]. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a>.)</p><p>Our approach to the use of myeloid growth factors depends upon the CLL regimen used and is discussed above. (See <a class="local">'Indications based on CLL therapy'</a> above.)</p><p class="headingAnchor" id="H339659082"><span class="h1">IMMUNOGLOBULIN REPLACEMENT</span><span class="headingEndMark"> — </span>The majority of patients with CLL either have or will develop hypogammaglobulinemia at some point in the course of their disease (see  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Humoral immunity'</a>). The use of prophylactic intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) to restore immunoglobulin (Ig)G levels is controversial. We generally reserve IVIG for selected patients who have recurrent serious infections.</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with CLL, prophylactic <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> is <strong>not</strong> recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with CLL who have had recurrent infections requiring intravenous (IV) antibiotics or hospitalization and who also have a serum IgG &lt;500 mg/dL, we suggest the administration of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>. The usual dose is 200 to 400 mg/kg by IV infusion, given as a single dose at three- to four-week intervals. We aim at maintaining the trough serum IgG in treated patients above 500 to 700 mg/dL as a general guideline. If there is a substantial decrease in the incidence of infections, treatment at gradually extended intervals may be considered. There is no good endpoint for when such therapy can be discontinued. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity", section on 'Administration and dosing'</a> and  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a>.)</p><p></p><p>Similarly, the routine use of prophylactic <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> is not recommended by the European Society of Medical Oncology or the International Workshop on Chronic Lymphocytic Leukemia clinical practice guidelines for CLL [<a href="#rid4">4,46</a>].</p><p>One large [<a href="#rid47">47</a>] and several small randomized trials and a meta-analysis have evaluated the use of prophylactic <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> in patients with CLL [<a href="#rid47">47-52</a>]. IVIG has not been directly compared with the use of prophylactic antimicrobials. The randomized trials of prophylactic IVIG found that patients who receive IVIG have a decreased incidence of minor and moderate, but not major, bacterial infections. However, IVIG does not appear to increase quality of life or survival.</p><p>The largest study evaluating the role of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> was a multicenter randomized trial in 84 patients with CLL who were at increased risk of bacterial infection due to hypogammaglobulinemia, a history of infection, or both [<a href="#rid47">47</a>]. Patients received IVIG (400 mg/kg) or placebo, each administered every three weeks for one year. Although minor or moderate bacterial infections were significantly less common in patients receiving IVIG, there was no impact on the incidence of major infections, mortality, or nonbacterial infections. It was found that routine IVIG therapy was not cost-effective.</p><p>Potential toxicities related to <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> include anaphylaxis, fever, chills, "flu-like" symptoms, and headache. In addition, potentially severe hemolytic reactions may be seen. (See  <a class="medical medical_review" href="/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p>The optimal dose, schedule, and subset of patients who would benefit from prophylactic <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> are not clear. Another important aspect of IVIG therapy is that it replaces neither IgM nor IgA.</p><p class="headingAnchor" id="H339659089"><span class="h1">IMMUNIZATIONS</span><span class="headingEndMark"> — </span>Vaccines are important for patients with CLL, but generally they should not be given during periods of immunosuppression from chemotherapy or immunotherapy because, at such times, they may not be effective, and live vaccines may result in vaccine-derived infections. The following figure summarizes immunization recommendations  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1</a>). Immunizations in patients with cancer (including recommendations regarding the appropriate timing of vaccinations) are discussed in greater detail separately, as are coronavirus disease 2019 vaccination recommendations for patients with cancer. (See  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a>.)</p><p>A fatal case of vaccine-derived disseminated varicella-zoster infection was reported in a 79-year-old man with CLL who received zoster vaccine six months after completing six cycles of <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>; his remission status was not reported [<a href="#rid53">53</a>]. The long-lasting immune effects of fludarabine and rituximab therapy as well as his advanced age may have predisposed this patient to disseminated infection.</p><p>Although a variety of immunizations have been studied in CLL patients, these have shown suboptimal responses due to impaired antibody production and defects in antigen presentation [<a href="#rid54">54-56</a>]. Most analyses have been small patient series. Superior responses may be obtained with protein and conjugated vaccines compared with polysaccharide vaccines in CLL patients [<a href="#rid56">56</a>].</p><p>A recombinant herpes zoster virus vaccine is approved for immunocompetent adults at least 50 years of age [<a href="#rid57">57</a>]. Efficacy and safety of this vaccine has been studied in cancer patients, including those with CLL, to ascertain efficacy as well as adverse effects. Recommendations for use of this vaccine in immunocompromised patients from the United States Centers for Disease Control and Prevention are now available [<a href="#rid58">58,59</a>]. (See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)", section on 'Immunocompromised persons'</a> and  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer", section on 'Zoster vaccine'</a>.)</p><p>Vaccinations for coronavirus disease 2019 (COVID-19) are reviewed separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.) </p><p class="headingAnchor" id="H1029060392"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Broad immune deficits</strong> − Infections have a major impact on the clinical course of patients with chronic lymphocytic leukemia (CLL). Patients with CLL have inherent immune defects in humoral and cell-mediated immunity that are related to the primary disease process, including hypogammaglobulinemia, abnormalities in T cell subsets, and defects in complement activity and neutrophil/monocyte function. Therapy-related immunosuppression has further impact on immune function in these patients. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Introduction'</a> and  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Immune defects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of infections</strong> − The spectrum of infections in CLL patients has changed over the past several decades with the introduction of CLL therapies that have specific effects on immune function, particularly on cell-mediated immunity. The infectious complications seen in these patients have evolved in relation to specific agents used. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Spectrum of infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis varies by therapeutic regimen</strong> − Since the immune defects rendered by specific CLL therapies have significant impact on subsequent infectious complications, our approach to prophylaxis varies depending upon the type of therapy used. We suggest the approach to therapy outlined in this table  (<a class="graphic graphic_table graphicRef95493" href="/d/graphic/95493.html" rel="external">table 1</a>) and in the text above (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Dosing for prophylactic antimicrobial regimens are summarized in this table  (<a class="graphic graphic_table graphicRef95619" href="/d/graphic/95619.html" rel="external">table 2</a>). (See <a class="local">'Antimicrobial prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antimicrobial prophylaxis is not advocated for patients with CLL who are not receiving active therapy or who are receiving an alkylating agent (eg, <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>), <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, or <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>. Instead, such patients are candidates for vigilant observation and early initiation of treatment if symptoms develop. (See <a class="local">'Indications based on CLL therapy'</a> above and <a class="local">'Alkylating agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients receiving a purine analog-based treatment regimen are at increased risk for several opportunistic infections. We use antiviral prophylaxis (against herpes simplex virus and varicella-zoster virus) in all patients receiving a purine analog. In those receiving a purine analog in combination with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> with or without an anti-CD20 monoclonal antibody, we also use <em>Pneumocystis</em> prophylaxis. (See <a class="local">'Purine analog therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients treated with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> are at increased risk for multiple opportunistic infections, including cytomegalovirus (CMV) reactivation. We use antiviral prophylaxis (against herpes simplex virus and varicella-zoster virus) and <em>Pneumocystis</em> prophylaxis routinely in such patients, and we monitor patients weekly for CMV reactivation. (See <a class="local">'Alemtuzumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At present, there are no standard recommendations for antimicrobial prophylaxis with BTK inhibitor use. (See <a class="local">'Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We use <em>Pneumocystis</em> pneumonia prophylaxis in all patients receiving <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a> or <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>. In patients with a history of CMV infection or positive CMV serology receiving idelalisib or duvelisib, regular clinical and laboratory monitoring for CMV infection should be performed. Such monitoring should also be considered in all patients receiving these agents, if feasible. For patients who develop CMV infection while receiving either agent and in whom the drug is reinstituted, monitoring with CMV polymerase chain reaction or CMV antigenemia should be performed at least monthly. An alternative to close monitoring is CMV prophylaxis; for patients receiving idelalisib or duvelisib, we determine the appropriateness of CMV prophylaxis on a case-by-case basis, balancing the risk of CMV reactivation with the risk of toxicity from CMV prophylaxis. (See <a class="local">'Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloid growth factors</strong> − The use of myeloid growth factors, such as granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF), in patients with CLL who are expected to have neutropenia should follow established guidelines for the management of infections in such patients. These are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IVIG for recurrent infections</strong> − The use of prophylactic intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) to restore immunoglobulin (Ig)G levels is controversial. We generally reserve IVIG for selected patients who have recurrent serious infections. (See <a class="local">'Immunoglobulin replacement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of vaccination and its timing</strong> − Vaccines are important for patients with CLL, but they should not be given during periods of immunosuppression from chemotherapy or immunotherapy because, at such times, they may not be effective and live vaccines may result in vaccine-derived infections. The following figure summarizes immunization recommendations  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1</a>). (See <a class="local">'Immunizations'</a> above and  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a>.)</p><p></p><p class="headingAnchor" id="H8657151"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Elias Anaissie, MD, and Kieren A Marr, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50:171.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2018. http://www.nccn.org (Accessed on August 01, 2018).</li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf (Accessed on October 22, 2018).</li><li><a class="nounderline abstract_t">Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131:2745.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Non-Hodgkin's lymphomas. Version 2.2014. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pd (Accessed on May 29, 2014).</li><li><a class="nounderline abstract_t">Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30:3209.</a></li><li><a class="nounderline abstract_t">Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378.</a></li><li><a class="nounderline abstract_t">Köppler H, Fuss H, Hurtz HJ, et al. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). Br J Haematol 2012; 158:238.</a></li><li><a class="nounderline abstract_t">Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27:491.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2013. http://www.nccn.org (Accessed on March 18, 2014).</li><li><a class="nounderline abstract_t">Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44:1947.</a></li><li><a class="nounderline abstract_t">Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19:3611.</a></li><li><a class="nounderline abstract_t">Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6.</a></li><li><a class="nounderline abstract_t">Morrison VA, Byrd JC, Peterson BL, et al. Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) study. Blood 2003; 102:440a.</a></li><li><a class="nounderline abstract_t">Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010; 28:4500.</a></li><li><a class="nounderline abstract_t">Kay NE, Wu W, Kabat B, et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 2010; 116:2180.</a></li><li><a class="nounderline abstract_t">Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25:793.</a></li><li><a class="nounderline abstract_t">Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079.</a></li><li><a class="nounderline abstract_t">Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4070.</a></li><li><a class="nounderline abstract_t">Lamanna N, Kay NE. Pentostatin treatment combinations in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009; 7:386.</a></li><li><a class="nounderline abstract_t">Wierda WG, Kipps TJ, Dürig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 117:6450.</a></li><li><a class="nounderline abstract_t">Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:498.</a></li><li><a class="nounderline abstract_t">Ferrajoli A, Keating MJ, O'Brien S, et al. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2011; 117:3182.</a></li><li><a class="nounderline abstract_t">Bertazzoni P, Rabascio C, Gigli F, et al. Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma 2010; 51:1485.</a></li><li><a class="nounderline abstract_t">Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23:1779.</a></li><li><a class="nounderline abstract_t">Tse E, Leung RY, Kwong YL. Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. Ann Hematol 2015; 94:165.</a></li><li><a class="nounderline abstract_t">Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31:2765.</a></li><li><a class="nounderline abstract_t">Byrd JC, Peterson BL, Rai KR, et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma 2009; 50:1589.</a></li><li><a class="nounderline abstract_t">Osterborg A, Foà R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23:1980.</a></li><li><a class="nounderline abstract_t">Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009; 144:95.</a></li><li><a class="nounderline abstract_t">Elter T, Vehreschild JJ, Gribben J, et al. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009; 88:121.</a></li><li><a class="nounderline abstract_t">Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3199.</a></li><li><a class="nounderline abstract_t">O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006; 7:125.</a></li><li><a class="nounderline abstract_t">O’Brien S, Ravandi-Kashani F, Wierda WG, et al. A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood 2005; 106:830a.</a></li><li><a class="nounderline abstract_t">O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111:1816.</a></li><li><a class="nounderline abstract_t">Smith TF, Espy MJ, Mandrekar J, et al. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis 2007; 45:1056.</a></li><li class="breakAll">National Comprehensive Cancer Network CLL/SLL Guidelines, Version 3.2012.</li><li class="breakAll">Zydelig. US Food and Drug Administration approved product information. Revised February 2018. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50 (Accessed on March 19, 2018).</li><li class="breakAll">ZYDELIG (idelalisib) tablets, for oral use. http://www.gilead.com/~/media/files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf?la=en (Accessed on December 14, 2016).</li><li class="breakAll">Copiktra (duvelisib), capsules for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf (Accessed on October 18, 2023).</li><li><a class="nounderline abstract_t">Ferrajoli A, Badoux XC, O’Brien S, et al. The combination therapy of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2010; 116:1395.</a></li><li><a class="nounderline abstract_t">Badoux X, O’Brien S, Wierda WG, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: Initial results of a phase II trial. Blood 2010; 116:2462.</a></li><li><a class="nounderline abstract_t">Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010; 24:1972.</a></li><li><a class="nounderline abstract_t">Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013; 31:584.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 Suppl 6:vi50.</a></li><li><a class="nounderline abstract_t">Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, Gale RP, Chapel HM, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988; 319:902.</a></li><li><a class="nounderline abstract_t">Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995; 17:75.</a></li><li><a class="nounderline abstract_t">Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81:121.</a></li><li><a class="nounderline abstract_t">Chapel H, Dicato M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 1994; 88:209.</a></li><li><a class="nounderline abstract_t">Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73:366.</a></li><li><a class="nounderline abstract_t">Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009; 50:764.</a></li><li><a class="nounderline abstract_t">Costa E, Buxton J, Brown J, et al. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Sinisalo M, Aittoniemi J, Käyhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44:649.</a></li><li><a class="nounderline abstract_t">Hartkamp A, Mulder AH, Rijkers GT, et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 2001; 19:1671.</a></li><li><a class="nounderline abstract_t">Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114:107.</a></li><li><a class="nounderline abstract_t">Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103.</a></li><li><a class="nounderline abstract_t">Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Clinical Considerations for Use of Recombinant Zoster Vaccine (RZV, Shingrix) in Immunocompromised Adults Aged ≥19 Years. https://www.cdc.gov/shingles/vaccination/immunocompromised-adults.html (Accessed on March 17, 2022).</li></ol></div><div id="topicVersionRevision">Topic 1405 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197731" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of elderly patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197731" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of elderly patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197731" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of elderly patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540348" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540348" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869884" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652068" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22571691" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075280" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075280" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14738148" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11504743" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393429" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20697069" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20187101" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17283364" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767648" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767647" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19606074" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pentostatin treatment combinations in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498674" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075274" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21246526" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578816" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19693094" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24879095" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775967" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19863336" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19626051" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016732" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682948" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169616" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026823" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18039954" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879925" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879925" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879925" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879925" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879925" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The combination therapy of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: Initial results of a phase II trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844565" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23270003" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21908504" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2901668" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7621634" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641639" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7803248" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492832" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19330654" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27147629" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12769342" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Vaccination against infections in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11166890" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472353" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370152" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051134" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
